Clinical outcomes in HTA appraisal reports of oncology medicines in Portugal: A cross-sectional analysis
Open Access
- 12 May 2026
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Abstract
Introduction: Reimbursement appraisals of medicines should emphasize outcomes clinically relevant to patients and clinicians. This study aims to characterize the outcomes selected in oncology reimbursement appraisal reports in Portugal. Methods: A cross-sectional analysis of public INFARMED pharmacotherapeutic appraisal reports for oncology medicines published in 2023–2024 was conducted. For each included report, we extracted efficacy and safety outcomes, their clinical relevance rating (critical/important), whether data were presented for analysis, and which outcomes were prioritized in the final decision rationale. Descriptive statistics were employed. Results: Fifty-four oncology reimbursement appraisals met the inclusion criteria. Overall survival was rated critical in 52/54 reports (96.3%) and prioritized in 29 (53.7%). Progression-free survival was rarely rated critical (n = 2, 3.7%) and was more often deemed important (n = 49, 90.7%), being prioritized in 15 (27.8%) reports. Quality of life was rated as critical in 52 (96.3%) reports but prioritized in only one (1.8%) decision. For safety, grade 3 to 4 AEs and mortality were graded as critical in 51 (94.4%) reports each, followed by discontinuation due to AEs (n = 50, 92.6%), although none of the appraisals prioritized safety outcomes in the final reimbursement decision. Conclusions: Overall survival predominates as the most influential outcome in Portuguese oncology drug reimbursement decisions. Progression-free survival is frequently used as a practical surrogate. Although quality of life and safety outcomes are commonly prioritized during scope-setting, they are not consistently reflected in decision rationales, underscoring the need to strengthen outcome reporting and evidence generation to better inform patient-centered reimbursement decisions.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (2024.05098.BDANA)
This publication has 29 references indexed in Scilit:
- Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023Advances in Therapy, 2024
- Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and ChallengesApplied Health Economics and Health Policy, 2024
- Real-World Evidence: A PrimerPharmaceutical Medicine, 2023
- Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 CountriesPharmacoEconomics - Open, 2022
- The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology AssessmentThe Patient - Patient-Centered Outcomes Research, 2021
- A review of the barriers to using Patient‐Reported Outcomes (PROs) and Patient‐Reported Outcome Measures (PROMs) in routine cancer careJournal of Medical Radiation Sciences, 2020
- What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countriesHealth Policy, 2019
- The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countriesQuality of Life Research, 2017
- The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literatureQuality of Life Research, 2016
- Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium GuidanceDrug Safety, 2013